Clinical trial Recruiting at 1 site Observational Ages 18 and up

One preoperative dose of paracetamol or ibuprofen to reduce opioids during and after septorhinoplasty

Official title: Comparison of the Effects of Single Dose Preemptive Paracetamol or Ibuprofen Administration Before Septrorhinoplasty on Intra- and Postoperative Opioid Consumption.

Run by Samsun University · NCT07337629 · Data updated 2026-11-12

This project will test whether giving one dose of paracetamol or ibuprofen before septorhinoplasty cuts down opioid use during and after surgery.

More Analgesia trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment54 (estimated)
SponsorSamsun University
Academic / other
Locations1 site (Samsun)
StatusRecruiting
StartedNovember 24, 2025
Main results expectedNovember 24, 2026
Study endsNovember 24, 2026
Registry record updatedJanuary 13, 2026
Trial IDNCT07337629 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18–65 with ASA physical status I–II scheduled for septorhinoplasty who can give informed consent and are not taking anticoagulants are ideal candidates.

Probably not a fit

Patients with serious renal, hepatic, cardiovascular or pulmonary disease, allergy to paracetamol or ibuprofen, bleeding disorders, pregnancy or current anticoagulant use are unlikely to benefit or be eligible.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, observational study using face-to-face interviews at the Ear, Nose and Throat Operating Room and Anesthesiology Clinic of Samsun University Training and Research Hospital. Patients scheduled for septorhinoplasty who meet inclusion criteria will receive preoperative paracetamol or ibuprofen and their intraoperative and postoperative opioid consumption will be recorded. The study will also track drug side effects and patient-reported outcomes using a validated 15-question Turkish quality scale. Enrollment is planned from November 1, 2025 through August 31, 2026 with a sample size increased above the minimum calculated 45 participants to allow for attrition.

Why it matters

Potential benefit: If successful, this could reduce the amount of opioid pain medication needed during and after septorhinoplasty and lower opioid-related side effects.

How similar studies have gone: Prior randomized and observational work has shown that preemptive paracetamol or NSAIDs can reduce postoperative opioid consumption and pain scores, so the approach builds on existing evidence.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Septorhinoplasty surgery
* ASA1-2 patients
* Men and women aged 18-65
* Informed consent and acceptance to participate in the study

Exclusion Criteria:

* ASA 3-4 and under 18 years of age
* Patients with serious renal, hepatological, cardiovascular, or pulmonary system diseases
* Allergy to paracetamol or ibuprofen
* Patients with bleeding diathesis, platelet dysfunction, GI disease, peptic ulcers, pregnancy, planning pregnancy, and breastfeeding mothers
* Patients using ASA or anticoagulants

Where it's running

  • Samsun University Samsun Training and Research Hospital
    Samsun, Turkey (Türkiye)
    Recruiting

Study contacts

  • Principal investigator: Hasan Cetinkaya, M.D. — Samsun University Samsun Educational and Research Hospital
  • Study coordinator: Hasan Cetinkaya, M.D.
  • Email: drhasancetinkaya@gmail.com
  • Phone: 5464799240

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.